Paul M. Michaels was appointed Interim CEO and Director. Mr. Michaels has business and investment experience in Japan and the U.S. with noteworthy expertise in the Life Sciences sector. He has completed transactions involving companies such as Celgene Corporation, Sumitomo Pharmaceuticals, Nobelpharma Co., Ltd, Teva Pharmaceuticals, ICOS, Neurocrine, Cell Therapeutics and Gilead Sciences.
Celgene Corp trading at $108 Revenue: $15.28 billion USD (2018)
Paul subsequently founded Nobelpharma, Ltd. Japan, an affiliate of Inabata & Co. Ltd., which is now one of Japan’s most profitable orphan drug companies. As President of the U.S. division and a co-Founder,he secured $35 million in initial capital and negotiated the license for the first designated orphan drug product in the company’s pipeline from Teva Pharmaceuticals.
ICOS Icos Corporation (trademark ICOS) was an American biotechnology company and the largest biotechnology company in the U.S. state of Washington, before it was sold to Eli Lilly and Company in 2007.
Neurocrine
In 1995, the company collaborated with Belgium-based Janssen Pharmaceutica N.V. to develop treatments for psychiatric disorders utilizing corticotropin releasing factor (CRF) antagonists, a class of compounds to treat psychiatric, neurological and gastrointestinal diseases including anxiety, depression and irritable bowel syndrome.[9] The company underwent an IPO in May 1996, listing on the NASDAQ exchange under the symbol NBIX and raising $34.2 million.
NBIX trading at $85.90
Gilead
GILD trading $73
Gilead Sciences' Remdesivir Is Being Used to Treat Coronavirus Patients
- Small molecule drug that penetrates the blood-brain barrier and activates PKC enzymes, resulting in improved synaptic function, new synapse formation, repair of damaged synapses, and prevention of neuronal death in Alzheimer’s. Neurology Phase 2 Product Novel first-in-class drug with ground-breaking potential utilizing a unique delivery method to slow or stop the progression of Glaucoma and dry AMD - neurodegenerative diseases and leading causes of blindness
- Reformulation of steroid for delayed release in the intestinal tract thus reducing prototypical side effect profile of orally administered steriods
- Immuno resistant device holding stem cells, allowing them to produce insulin without triggering the body's T-Cell response
- Reformulation of topical into oral formulation for various blood cancers
- Licensed device from University that creates Apoptosis in patients reducing inflammation in major organs and blood vessels
- Novel first-in-class drug with ground-breaking potential utilizing a unique delivery method to slow or stop the progression of Glaucoma and dry AMD - neurodegenerative diseases and leading causes of blindness
-Low cost universal insulin delivery system licensed form large pharma for initial 510K approval expected within 12 months
- Reformulation of topical into oral formulation for various blood cancers
News 
Market Data 
Discover 
